Individual levels of miR-223 and the genes PRDM1, SAV1 and FLT1 all had good biomarker ability to discriminate ccRCC patients that were responders from non-responders (AUC > 0.7). This evidence concerns the gene SAV1 and nonpapillary renal cell carcinoma.